Aug 29, 2022
Acute respiratory distress syndrome (ARDS) is a rapidly progressing condition that affects critically ill people. The major complication of ARDS is fluid leaking into the lungs, which makes breathing difficult or impossible. Shortness of breath, cough, and fever are among ARDS symptoms; in certain cases, high heart...
Read More...
Aug 26, 2022
Despite decades of research, treatment options are limited in the ARDS market. There are only a few treatments available in the ARDS market. The mainstay of management remains supportive care with mechanical ventilation. Other ARDS treatment options for patients include supplemental oxygen, prone positioning, the u...
Read More...
Aug 22, 2022
The acute respiratory distress syndrome (ARDS) prevalence is increasing every year; it is estimated that in the United States alone, about 190K Americans are diagnosed with ARDS each year. Prior to the COVID-19 global pandemic, more than 700K individuals in the US and 2 million cases globally developed ARDS from tr...
Read More...
Jun 09, 2020
Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys...
Read More...
Apr 15, 2020
The Novel Coronavirus since its outbreak in Wuhan China in November-2019 has infected around 1,848,439 people with 117,217 confirmed deaths in 213 countries, till date. Countries around the world are working tirelessly to tackle the current situation. Local Governments in order to reduce the pace of corona...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper